[go: up one dir, main page]

MX2017007381A - Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. - Google Patents

Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.

Info

Publication number
MX2017007381A
MX2017007381A MX2017007381A MX2017007381A MX2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A MX 2017007381 A MX2017007381 A MX 2017007381A
Authority
MX
Mexico
Prior art keywords
maf
musculoadoneurotic
oncogen
homology
human fibrosarcoma
Prior art date
Application number
MX2017007381A
Other languages
English (en)
Inventor
Gomis Roger
Carlos Tercero Juan
Original Assignee
Inbiomotion Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inbiomotion Sl filed Critical Inbiomotion Sl
Publication of MX2017007381A publication Critical patent/MX2017007381A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/57575—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)

Abstract

La presente descripción se relaciona con miembros de unión, especialmente moléculas de anticuerpo las cuales se unen a Maf humano. Los miembros de unión son útiles para la determinación del nivel de expresión de Maf.
MX2017007381A 2014-12-11 2015-12-11 Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano. MX2017007381A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462090599P 2014-12-11 2014-12-11
PCT/IB2015/059562 WO2016092524A1 (en) 2014-12-11 2015-12-11 Binding members for human c-maf

Publications (1)

Publication Number Publication Date
MX2017007381A true MX2017007381A (es) 2017-11-06

Family

ID=55024191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007381A MX2017007381A (es) 2014-12-11 2015-12-11 Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.

Country Status (10)

Country Link
US (1) US10793642B2 (es)
EP (1) EP3229909B1 (es)
JP (1) JP2017538412A (es)
KR (1) KR20170093182A (es)
CN (1) CN107001480B (es)
AU (1) AU2015358868A1 (es)
BR (1) BR112017012515A2 (es)
CA (1) CA2967224C (es)
MX (1) MX2017007381A (es)
WO (1) WO2016092524A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX344315B (es) 2010-10-06 2016-12-13 Institució Catalana De Recerca I Estudis Avancats Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104603288B (zh) 2012-06-06 2018-12-14 生物医学研究机构基金会 用于肺癌转移的诊断、预后和治疗的方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP3553186B1 (en) 2012-10-12 2021-11-17 Inbiomotion, S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
EP3272880B1 (en) 2013-03-15 2020-11-25 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
AU2015358868A1 (en) 2014-12-11 2017-06-01 Inbiomotion S.L. Binding members for human C-Maf
EP3458610B1 (en) 2016-05-25 2021-05-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9509957D0 (en) 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
ES2144386T5 (es) 1996-12-23 2012-12-07 Immunex Corporation Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) * 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
JP4562286B2 (ja) 1998-12-10 2010-10-13 ブリストル−マイヤーズ スクウィブ カンパニー 抗体模倣物および他の結合タンパク質のタンパク質骨格
DK1178958T3 (da) 1999-03-15 2004-06-21 Axys Pharm Inc N-cyanomethylamider som proteaseinhibitorer
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
EP1272668B1 (en) 2000-04-03 2007-02-14 Corixa Corporation Methods, compositions and kits for the detection and monitoring of breast cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP3492100B1 (en) 2001-06-26 2021-12-08 Amgen Inc. Antibodies to opgl
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2005046731A1 (en) 2003-10-17 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
EP3211086B1 (en) 2005-09-20 2021-06-09 Menarini Silicon Biosystems S.p.A. Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ATE552505T1 (de) 2006-06-30 2012-04-15 Univ Southern California Quantifizierbare interne referenzstandards für immunhistochemie und verwendung
WO2008086800A2 (en) 2007-01-15 2008-07-24 Aarhus Universitet Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
CA2676791A1 (en) 2007-02-16 2008-11-06 Pacific Arrow Limited Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
CN104231082B (zh) 2007-05-24 2018-12-21 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
JPWO2010110346A1 (ja) 2009-03-24 2012-10-04 独立行政法人理化学研究所 白血病幹細胞マーカー
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
MX344315B (es) 2010-10-06 2016-12-13 Institució Catalana De Recerca I Estudis Avancats Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
CN104603288B (zh) 2012-06-06 2018-12-14 生物医学研究机构基金会 用于肺癌转移的诊断、预后和治疗的方法
EP3553186B1 (en) 2012-10-12 2021-11-17 Inbiomotion, S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
EP3272880B1 (en) 2013-03-15 2020-11-25 Fundació Institut de Recerca Biomèdica (IRB Barcelona) Method for the diagnosis, prognosis and treatment of metastatic cancer
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
ES2727904T3 (es) 2013-10-09 2019-10-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastatizante del hueso que se origina a partir de cáncer de mama
AU2015358868A1 (en) 2014-12-11 2017-06-01 Inbiomotion S.L. Binding members for human C-Maf
EP3458610B1 (en) 2016-05-25 2021-05-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status
AU2018372762B2 (en) 2017-11-22 2025-08-21 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-maf status

Also Published As

Publication number Publication date
WO2016092524A1 (en) 2016-06-16
CA2967224A1 (en) 2016-06-16
CN107001480B (zh) 2021-12-03
US20170369589A1 (en) 2017-12-28
US10793642B2 (en) 2020-10-06
CA2967224C (en) 2023-08-22
AU2015358868A1 (en) 2017-06-01
EP3229909A1 (en) 2017-10-18
BR112017012515A2 (en) 2018-01-02
CN107001480A (zh) 2017-08-01
KR20170093182A (ko) 2017-08-14
EP3229909B1 (en) 2020-10-14
JP2017538412A (ja) 2017-12-28

Similar Documents

Publication Publication Date Title
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
MX2017007381A (es) Miembros de union para homologo del oncogen de fibrosarcoma musculoadoneurotico (c-maf) humano.
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
GEAP202114450A (en) Anti-tigit antibodies
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
UY34885A (es) Proteínas de unión anti-mesotelina
EA202092435A3 (ru) Моноклональные антитела против bcma
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
PL3101032T3 (pl) Koniugat przeciwciało anty-HER2-lek
HUE053457T2 (hu) Multispecifikus ellenanyag-konstrukciók
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
MX2016016886A (es) Anticuerpos anti-axl.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
SI3200822T1 (sl) Vezavne molekule, posebno antiteles, vezanih na L1CAM (CD171)
EP3251607C0 (en) ACHILLES TENDON SUTURE INSTRUMENT
IL269559A (en) Stable multispecific antibodies
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EP3756626C0 (en) ASTRAGALOCALCANEAN JOINT IMPLANT
EP3589320A4 (en) ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION
DK3154587T3 (da) Konjugater omfattende et anti-egfr1-antistof
EP3476207A4 (en) SEEDS CUP